Pfizer profit beats estimates on higher demand for COVID products
By Manas Mishra
July 28 (Reuters) – Pfizer Inc (PFE.N) beat second-quarter profit expectations on Thursday as its COVID-19 pill as well as vaccine remained in high demand following an uptick in infections in the United States.
Revenue from the antiviral pill, Paxlovid, exceeded market estimates by more than $1 billion, while vaccine sales surged 20%, helping the drugmaker reaffirm the combined 2022 revenue forecast of $54 billion.
Pfizer also kept its full-year sales forecast unchanged, despite taking a $2 billion hit due to a stronger dollar, sending its shares up 1% in premarket trading.
While its coronavirus vaccine powered much of its growth last year, its antiviral treatment Paxlovid, whose demand has surged in recent months, is expected to further bolster revenue.
Paxlovid sales of $8.1 billion beat expectations of $7 billion, according to Refinitiv data, as it becomes the most used COVID antiviral in the United States.
Pfizer has been banking on demand for vaccine boosters to drive up sales in the next few years.
The company and its partner BioNTech last month signed a $3.2 billion deal with the U.S. government for 105 million doses of their vaccine, which includes supply of retooled Omicron-adapted booster, pending regulatory clearance. read more
“One question that could be asked is why Pfizer maintained … COVID vaccine guidance despite getting an incremental $3 billion plus order from the US government,” said Wells Fargo analyst Mohit Bansal.
The company recorded a $450 million inventory write-off in the second quarter related to its COVID-19 products that had exceeded or are expected to exceed their shelf-lives.
Pfizer’s quarterly profit rose to $9.91 billion from $5.56 billion last year. Excluding items, it earned $2.04 per share, above estimates of $1.78.
Our Standards: The Thomson Reuters Trust Principles.